Elevated BNP caused by recombinant human interleukin-11 treatment in patients with chemotherapy-induced thrombocytopenia
Elevated BNP caused by recombinant human interleukin-11 treatment in patients with chemotherapy-induced thrombocytopenia
复制标题
重组人白细胞介素-11治疗化疗后血小板减少患者BNP水平升高
DOI：
10.1007/s00520-019-04734-z
复制
发表时间：
2019-11-01
影响因子：
3.1
通讯作者：
Lu, Yue
中科院分区：
文献类型：
--
作者：
Liu, Na-wei;Huang, Xin;Lu, Yue
血小板减少症是一种以血小板水平异常低为特征的病症，通常由化疗引起。重组人白细胞介素-11（rhIL-11）是一种可刺激血小板生成的细胞因子，常用于治疗血小板减少症。我们观察了24例白血病化疗后血小板减少患者应用重组人白细胞介素-11（rhIL-11）的副作用。为探讨rhIL-11对心血管系统的影响，我们检测了白血病患者化疗后血清脑钠肽（BNP）、血压波动、体重变化以及是否出现水肿或心力衰竭。结果显示，rhIL-11治疗后BNP水平明显升高（P < 0. 05）。05)但在2-4天后消退。此外，9名患者出现水肿和体重增加，4名患者出现急性左心衰竭。此外，rhIL-11给药前的平均血压为119/75 mmHg（范围139/86 mmHg至99/64 mmHg），rhIL-11给药后为127/79 mmHg（范围146/89 mmHg至108/69 mmHg）。总之，尽管rhIL-11对治疗化疗诱导的血小板减少症是有用的，但在使用rhIL-11期间，监测患者的临床状态并经常复查BNP水平是重要的。此外，老年患者应特别注意。然而，开始和停止rhIL-11治疗的适当时机需要进一步研究。
Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes and often induced by chemotherapy. Recombinant human interleukin-11 (rhIL-11) is a cytokine that can stimulate thrombopoiesis and is commonly used to treat thrombocytopenia. We observed the side effects of rhIL-11 in 24 leukemia patients with chemotherapy-induced thrombocytopenia. To determine the cardiovascular effects of rhIL-11, we detected changes in the patients' serum brain natriuretic peptide (BNP), blood pressure fluctuations, weight change, and whether edema or heart failure occurred in leukemia patients after chemotherapy. The results showed that BNP was significantly elevated after using rhIL-11 (P < 0. 05) but regressed after 2-4 days. Furthermore, nine patients had edema and experienced weight gain, and four experienced acute left heart failure. In addition, the average blood pressure was 119/75 mmHg (range 139/86 mmHg to 99/64 mmHg) before rhIL-11 administration and 127/79 mmHg (range 146/89 mmHg to 108/69 mmHg) after rhIL-11 use. In conclusion, although rhIL-11 is useful for treating chemotherapy-induced thrombocytopenia, it is important to monitor the patients' clinical status and re-examine BNP levels frequently during the use of rhIL-11. Furthermore, senile patients should be given special attention. However, the appropriate timing to begin and discontinue rhIL-11 treatment needs further investigation.